SAN DIEGO, Jan. 11, 2017 /PRNewswire/ -- Shareholder rights
law firm Johnson & Weaver, LLP has launched an investigation
into whether the board members of Derma Sciences, Inc. (NASDAQ:
DSCI) breached their fiduciary duties in connection with the
proposed sale of the Company to Integra LifeSciences Holdings
Corporation. Derma operates as a medical device company in the
wound care market.
On January 10, 2017, Derma
announced it had signed a definitive merger agreement with Integra.
Under terms of the agreement, Integra will acquire all of the
outstanding shares of Derma for $7
per share.
The investigation concerns whether the Derma board failed to
satisfy their duties to the Company shareholders, including whether
the board adequately pursued alternatives to the acquisition and
whether the board obtained the best price possible for Derma shares
of common stock. Nationally recognized Johnson & Weaver is
investigating whether the proposed deal price represents adequate
consideration, especially given one Wall Street analyst has a
$8.50 price target on the
stock.
If you are a shareholder of Derma and believe the proposed
buyout price is too low and you're interested in learning more
about the investigation or your legal rights and remedies, please
contact lead analyst Jim Baker
(jimb@johnsonandweaver.com) at 619-814-4471.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder
rights law firm with offices in California, New
York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonandweaver.com. Attorney advertising. Past results
do not guarantee future outcomes.
Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/derma-dsci-alert-johnson--weaver-llp-launches-an-investigation-into-the-fairness-of-price-and-process-in-proposed-sale-of-derma-sciences-inc-is-7-a-fair-price-300389351.html
SOURCE Johnson & Weaver, LLP
